Response and Toxicity to the Second Course of 3 Cycles of <sup>177</sup>Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer

Response and Toxicity to the Second Course of 3 Cycles of <sup>177</sup>Lu-PSMA Therapy Every 4 Weeks in Patients with Metastatic Castration-Resistant Prostate Cancer

Background: We investigated the response rate and degree of toxicity of a second course of three cycles of [<sup>177</sup>Lu]Lu-PSMA radioligand therapy (PSMA-RLT) every 4 weeks in mCRPC patients. Methods: Forty-three men (71.5 ± 6.6 years, median PSA 40.8 (0.87–1358 µg/L)) were studied....

Full description

Bibliographic Details
Main Authors: Sazan Rasul, Tim Wollenweber, Lucia Zisser, Elisabeth Kretschmer-Chott, Bernhard Grubmüller, Gero Kramer, Shahrokh F. Shariat, Harald Eidherr, Markus Mitterhauser, Chrysoula Vraka, Werner Langsteger, Marcus Hacker, Alexander R. Haug
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
PSMA-RLT
<sup>177</sup>Lu-PSMA
PSA
mCRPC
prostate cancer
Online Access:https://www.mdpi.com/2072-6694/13/10/2489

Internet

https://www.mdpi.com/2072-6694/13/10/2489

Similar Items